Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.

doi:10.1007/s11523-022-00933-7

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.

Targeted oncology - 1 Jan 2023

Rimini Margherita, Fabregat-Franco Carles, Persano Mara, Burgio Valentina, Bergamo Francesca, Niger Monica, Scartozzi Mario, Rapposelli Ilario Giovanni, Aprile Giuseppe, Ratti Francesca, Pedica Federica, Verdaguer Helena, Rizzato Mario, Nichetti Federico, Lai Eleonora, Cappetta Alessandro, Macarulla Teresa, Fassan Matteo, De Braud Filippo, Pretta Andrea, Simionato Francesca, De Cobelli Francesco, Aldrighetti Luca, Fornaro Lorenzo, Cascinu Stefano, Casadei-Gardini Andrea

Abstract excerpt

BACKGROUND: Isocitrate dehydrogenase-1 (IDH1) mutations occur in a significant proportion of intrahepatic cholangiocarcinomas (iCCAs). No data are available regarding the prognostic impact of IDH1 mutations in advanced iCCA patients after progression on first-line therapies. OBJECTIVE: We investigated the role of IDH1 mutation in advanced iCCA after progression on first-line therapies. PATIENTS AND METHODS: After...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bile Duct Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bile Ducts, Intrahepatic

Share to Cholangiocarcinoma

Share to Cholangiocarcinoma and Gallbladder Cancer Studies

Share to Gallbladder and Bile Duct Disorders

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Prognosis

Source

Open in PubMed

Identifiers

PMID: 36689074
DOI: 10.1007/s11523-022-00933-7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Outcomes After Progression on First-Line Therapies in IDH1 Mutated Versus Wild-Type Intrahepatic Cholangiocarcinoma Patients.PMID 36689074Read ↗

Impact of IDH1 mutation on clinical course of patients with intrahepatic cholangiocarcinoma: a retrospective analysis from a German tertiary center.Semantic proximity Read ↗

Mutation Rate of IDH1 and the Impact of Pathological Features on Survival in Intrahepatic CholangiocarcinomaSemantic proximity Read ↗

Isocitrate Dehydrogenase-Mutated Cholangiocarcinoma: Natural History and Clinical Outcomes.Semantic proximity Read ↗

Association of IDH1 mutations with survival and recurrence in resected intrahepatic cholangiocarcinoma received or not received adjuvant chemotherapy.Semantic proximity Read ↗

Evaluating the Prognostic Impact of IDH Mutations in Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Next-generation sequencing analysis of cholangiocarcinoma identifies distinct IDH1-mutated clusters.Semantic proximity Read ↗

Molecular profile and its clinical impact of IDH1 mutated versus IDH1 wild type intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Differential isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 mutation-related landscape in intrahepatic cholangiocarcinoma.Semantic proximity Read ↗

Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Isocitrate dehydrogenase 1 mutation sensitizes intrahepatic cholangiocarcinoma cells to MDM2 inhibitorsSemantic proximity Read ↗

Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.Semantic proximity Read ↗

Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.